3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
8
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
4
Carcinoma, Renal Cell
3
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Melanoma
1
Kidney Neoplasms
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
75
Nivolumab
46
Cyclophosphamide
25
aldesleukin
23
fludarabine
16
atezolizumab
15
Ipilimumab
15
Interleukin-2
14
Radiosurgery
13
Paclitaxel
13
Specimen Handling
12
Magnetic Resonance Spectroscopy
11
Carboplatin
11
fludarabine phosphate
9
Docetaxel
9
durvalumab
8
Cisplatin
8
cemiplimab
7
Bevacizumab
7
Radiotherapy
6
Gemcitabine
6
Biopsy
6
spartalizumab
5
avelumab
5
Pemetrexed
5
Oxaliplatin
5
Immune Checkpoint Inhibitors
5
Filgrastim
5
Cryosurgery
5
Blood Specimen Collection
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Colony-Stimulating Factors
×
Genitourinary
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled